

Supplemental Table 1: Fold reduction in relative affinity for r/hCRF and rUcn 1 as a result of alanine substitution of the indicated amino acids of human CRF-BP.

mutant	r/hCRF		rUcn 1	
	fold reduction in relative affinity	95% confidence intervals	fold reduction in relative affinity	95% confidence intervals
WT	1.00	(0.849 to 1.18)	1.00	(0.765 to 1.31)
E27A	0.906	(0.718 to 1.14)	0.499	(0.415 to 0.601)
E30A	1.23	(0.974 to 1.55)	1.09	(0.903 to 1.31)
D33A	0.711	(0.564 to 0.897)	0.786	(0.652 to 0.946)
D35A	0.926	(0.734 to 1.17)	0.955	(0.793 to 1.15)
K45A	0.667 ¹⁾	(0.561 to 0.793)	0.946	(0.806 to 1.11)
R46A	1.08	(0.912 to 1.29)	1.07	(0.908 to 1.25)
E47A	1.26	(1.06 to 1.50)	0.883	(0.752 to 1.04)
L48A	0.986	(0.860 to 1.13)	1.06	(0.930 to 1.20)
E51A	0.830	(0.692 to 0.994)	0.568	(0.472 to 0.682)
Y54A	3.94	(3.32 to 4.68)	1.12	(0.953 to 1.31)
R55A	1.58	(1.33 to 1.88)	1.28	(1.09 to 1.50)
R56A	133	(123 to 145)	2.05	(1.87 to 2.25)
L58A	3.39	(2.84 to 4.04)	1.76	(1.41 to 2.20)
R59A	1.75	(1.47 to 2.09)	1.01	(0.860 to 1.19)
L61A	6.69	(5.58 to 8.02)	22.0	(18.2 to 26.7)
D62A	95.7	(85.1 to 107)	1.44	(1.20 to 1.72)
M63A	1.11	(0.967 to 1.27)	7.76	(6.53 to 9.21)
L64A	2.33	(2.03 to 2.67)	1.13	(0.951 to 1.34)
F70A	6.45	(5.59 to 7.45)	1.35	(1.20 to 1.52)
F72A	no expression		no expression	
D75A	1.52	(1.32 to 1.74)	1.50	(1.26 to 1.78)
R76A	0.976	(0.814 to 1.17)	0.765	(0.637 to 0.92)
Q78A	1.60	(1.39 to 1.83)	1.62	(1.37 to 1.93)
F84A	1.79	(1.56 to 2.05)	33.9	(28.5 to 40.3)
F85A	3.11	(2.70 to 3.58)	4.08	(3.63 to 4.59)
E88A	1.33	(1.16 to 1.54)	2.34	(2.09 to 2.64)
E90A	0.878	(0.762 to 1.01)	1.11	(0.984 to 1.24)
E91A	1.14	(1.01 to 1.29)	2.28	(2.04 to 2.54)
Y97A	1.10	(0.958 to 1.27)	0.918	(0.817 to 1.03)
D98A	no expression		no expression	
D103A	1.10	(0.957 to 1.26)	1.22	(1.03 to 1.45)
D108A	0.783	(0.678 to 0.903)	0.744	(0.626 to 0.884)
F109A	1.28	(1.11 to 1.47)	1.15	(1.02 to 1.29)
K111A	1.84	(1.64 to 2.06)	1.75	(1.57 to 1.96)
F113A	no expression		no expression	
D114A	no expression		no expression	
W116A	no detectable binding		no detectable binding	
K119A	1.17	(1.05 to 1.31)	1.12	(1.00 to 1.25)
E121A	3.88	(3.46 to 4.34)	5.92	(5.29 to 6.63)
K122A	0.806	(0.719 to 0.903)	1.07	(0.958 to 1.20)
F123A	5.19	(4.51 to 5.98)	5.66	(5.03 to 6.36)
S125A	1.91	(1.66 to 2.20)	1.51	(1.34 to 1.70)
D128A	1.83	(1.60 to 2.10)	2.52	(2.12 to 3.00)
H129A	1.41	(1.23 to 1.61)	1.55	(1.30 to 1.84)
R136A	1.72	(1.49 to 1.98)	1.35	(1.02 to 1.51)
Y137A	1.59	(1.38 to 1.83)	1.05	(0.938 to 1.19)
D139A	1.04	(0.901 to 1.19)	0.856	(0.762 to 1.04)
E142A	0.737	(0.615 to 0.883)	0.758	(0.631 to 1.10)
R147A	0.876	(0.731 to 1.05)	0.733	(0.610 to 0.882)
R148A	1.31	(1.10 to 1.57)	0.989	(0.823 to 1.19)
R151A	1.28	(1.13 to 1.45)	1.14	(1.01 to 1.30)
S152A	1.40	(1.24 to 1.59)	1.31	(1.15 to 1.49)
S153A	1.09	(0.960 to 1.23)	0.818	(0.719 to 0.931)
Q154A	1.82	(1.61 to 2.06)	2.02	(1.77 to 2.30)
N155A	no expression		no expression	
F160A	1.46	(1.33 to 1.61)	1.29	(1.15 to 1.44)
F161A	no expression		no expression	
R162A	1.49	(1.31 to 1.69)	1.20	(1.05 to 1.36)
F170A	no expression		no expression	
K175A	1.75	(1.52 to 2.02)	1.58	(1.41 to 1.78)
N179A	1.56	(1.35 to 1.80)	1.61	(1.43 to 1.81)
P182A	0.766	(0.695 to 0.845)	0.836	(0.746 to 0.936)
N184A	no expression		no expression	
I186A	1.02	(0.899 to 1.15)	1.46	(1.28 to 1.67)
S187A	1.57	(1.39 to 1.78)	1.88	(1.65 to 2.14)
Q188A	2.44	(2.21 to 2.70)	8.03	(7.16 to 8.99)
T189A	3.52	(3.05 to 4.05)	5.17	(4.60 to 5.81)
F194A	1.04	(0.922 to 1.17)	1.15	(1.03 to 1.28)
T195A	1.30	(1.15 to 1.47)	1.22	(1.07 to 1.38)
Q201A	0.815	(0.723 to 0.920)	0.972	(0.873 to 1.08)
H202A	0.801	(0.710 to 0.904)	0.807	(0.725 to 0.899)
N204A	1.28	(1.11 to 1.47)	1.02	(0.908 to 1.15)
F207A	2.23	(1.97 to 2.53)	2.54	(2.23 to 2.89)
Y211A	no detectable binding		no detectable binding	
R203A	1.24	(0.926 to 1.67)	0.978	(0.744 to 1.29)
D219A	1.61	(1.20 to 2.16)	1.64	(1.26 to 2.14)
R46A/R59A	1.17	(0.985 to 1.39)	0.627	(0.534 to 0.736)
C237A/C264A	1.22	(1.03 to 1.45)	1.05	(0.894 to 1.23)
C277A/C318A	1.04	(0.923 to 1.16)	0.927	(0.829 to 1.04)

¹⁾ statistically significant differences in the relative potency of CRF or Ucn1 compared to WT CRF-BP are highlighted in grey. Larger shifts in potency are indicated by progressively darker shades of grey.